Header Logo

Connection

MICHELLE A FANALE to Angiogenesis Inhibitors

Back to Details
This is a "connection" page, showing publications MICHELLE A FANALE has written about Angiogenesis Inhibitors.
MICHELLE A FANALE
Connection Strength
0.097
Angiogenesis Inhibitors
  1. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882.
    View in: PubMed
    Score: 0.097
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.